Research output per year
Research output per year
- 18 results
Search results
-
2026
Pharmaceutical company promotional payments to English general practices: longitudinal study
Mulinari, S., Malik, M., Larkin, J., Elsharkawy, M., Fahey, T., Moriarty, F. & Ozieranski, P., 2026, In: BJGP open. 10, 1, BJGPO.2024.0281.Research output: Contribution to journal › Article › peer-review
Open Access -
Unknowns of drug company payment disclosure: why the UK needs payment transparency legislation
Ozieranski, P., Rickard, E. & Mulinari, S., 2026, In: BMJ Evidence-Based Medicine. 31, 1, p. 7-12Research output: Contribution to journal › Article › peer-review
Open Access -
2025
Patterns of company misconduct, recidivism, and complaint resolution delays: A temporal analysis of UK pharmaceutical industry self-regulation within the European context
Mulinari, S., Pashley, D. & Ozieranski, P., 2025, In: Regulation and Governance. 19, 1, p. 200-217Research output: Contribution to journal › Article › peer-review
Open Access -
Pharmaceutical industry payments to patient organizations in Poland: Analysis of the patterns, evolution, and structure of connections
Makowska, M., Mulinari, S. & Ozieranski, P., 2025, In: International journal of social determinants of health and health services. 55, 2, p. 199-212 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
2024
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019: A content analysis
Larkin, J., Matthes, B., Azribi, M., Kearns, C., Mulinari, S., Rickard, E., Moriarty, F., Fahey, T. & Ozieranski, P., 2024 Nov, In: Health Policy. 149, November 2024, 105155.Research output: Contribution to journal › Article › peer-review
Open Access -
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: An observational study
Larkin, J., Mulinari, S., Ozieranski, P., Lynch, K., Fahey, T., Ozaki, A. & Moriarty, F., 2024 Apr 15, In: Health Policy and Technology. 13, 2, 100865.Research output: Contribution to journal › Article › peer-review
Open Access -
2023
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
Ozieranski, P., Saghy, E. & Mulinari, S., 2023 Nov 1, In: PLoS ONE. 18, 11, e0290022.Research output: Contribution to journal › Article › peer-review
Open Access -
Unethical pharmaceutical marketing: a common problem requiring collective responsibility
Mulinari, S. & Ozieranski, P., 2023 Sept 19, In: BMJ (Clinical research ed.). 382, e076173.Research output: Contribution to journal › Article › peer-review
Open AccessFile253 Downloads (Pure) -
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
Ozieranski, P., Saito, H., Rickard, E., Mulinari, S. & Ozaki, A., 2023 Mar 4, In: Globalization and Health. 19, 14, p. 1-42Research output: Contribution to journal › Article › peer-review
Open AccessFile171 Downloads (Pure) -
2022
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
Fabbri, A., Mulinari, S., Johansson, M., Ghaur, W., Khalil, A. M. & Lundh, A., 2022 Nov 27, In: BMC Medical Education. 22, 812.Research output: Contribution to journal › Article › peer-review
Open AccessFile75 Downloads (Pure) -
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
Mulinari, S., Pashley, D. & Ozieranski, P., 2022 Nov 8, In: Health Policy. 126, 12, p. 1256-1262Research output: Contribution to journal › Article › peer-review
Open AccessFile111 Downloads (Pure) -
Capitalizing on transparency: commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
Mulinari, S. & Ozieranski, P., 2022 Feb 9, In: Big Data and Society. 9, 1Research output: Contribution to journal › Article › peer-review
Open Access -
A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding
Ozieranski, P., Janos, P., Rickard, E., Mulinari, S. & Csanadi, M., 2022 Jan 23, In: Sociology of Health & Illness. 44, 1, p. 188-210Research output: Contribution to journal › Article › peer-review
Open AccessFile92 Downloads (Pure) -
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
Pashley, D., Ozieranski, P. & Mulinari, S., 2022, In: International Journal of Health Services. 52, 3, p. 347-362Research output: Contribution to journal › Article › peer-review
Open AccessFile133 Downloads (Pure) -
Tip of the iceberg? Country- and company-level analysis of drug company payments for research and development in Europe
Ozieranski, P., Martinon, L., Jachiet, P.-A. & Mulinari, S., 2022, In: International Journal of Health Policy and Management. 11, 12, p. 2842-2859Research output: Contribution to journal › Article › peer-review
Open Access -
2021
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: A European policy review
Ozieranski, P., Martinon, L., Jachiet, P.-A. & Mulinari, S., 2021 Dec 16, In: BMJ Open. 11, e053138.Research output: Contribution to journal › Article › peer-review
Open AccessFile182 Downloads (Pure) -
Drug company payments to General Practices in England: cross-sectional and social network analysis
Saghy, E., Mulinari, S. & Ozieranski, P., 2021 Dec 7, In: PLoS ONE. 16, 12, e0261077.Research output: Contribution to journal › Article › peer-review
Open AccessFile118 Downloads (Pure) -
Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries
Mulinari, S., Martinon, L., Jachiet, P.-A. & Ozieranski, P., 2021 Jul 1, In: Health Policy. 125, 7, p. 915-922 8 p.Research output: Contribution to journal › Article › peer-review
Open Access